PedAM
Pediatric Disease Annotations & Medicines
| Disease | prostate cancer |
| Symptom | C0153690|bone metastasis |
| Sentences | 83 |
| PubMedID- 22199272 | Treatment of bone metastasis in prostate cancer: efficacy of a novel polybisphosphonate. |
| PubMedID- 21327451 | Background: we aimed to assess the diagnostic accuracy of serum osteoclastogenesis markers for detection of bone metastasis in patients with prostate cancer (pca) and to assess the usefulness of these markers as predictors of mortality from pca. |
| PubMedID- 21111244 | In this review, clinical evidence regarding the efficacy and safety of currently available bone-targeted therapies including bisphosphonates and anti-rankl monoclonal antibody in the treatment of bone metastasis due to breast cancer, prostate cancer, lung cancer, and multiple myeloma bone disease will be summarized. |
| PubMedID- 21738117 | Aim: the aim of this paper was to compare the diagnostic performance of positron emission tomography/computed tomography (pet/ct) with fluorocholine (18f) (fch) or fluoride(18f) (fna) for the detection of bone metastasis in patients with prostate cancer complaining from osteoarticular pain, taking into account whether they were referred for initial staging or recurrence localization. |
| PubMedID- 21090348 | Objective: to screen serum biomarker candidates in prostate cancer with bone metastasis by two-dimensional gel electrophoresis (2-dge) and mass spectrometry. |
| PubMedID- 23803117 | Retrospective study of predictors of bone metastasis in prostate cancer cases. |
| PubMedID- 23214246 | Conclusion: 153sm-edtmp is an ideal agent for the treatment of prostate cancer with bone metastasis. |
| PubMedID- 26078757 | It is expressed on osteoclast precursors, mature osteoclasts, dendritic cells, b and t cells, fibroblasts, articular chondrocytes, and some cancer cells including breast and prostate cancers, tumours with very high bone metastasis potential . |
| PubMedID- 22720236 | Thus, targeting treg cells may not only improve anti-tumor immunity, but also ameliorate bone pathology in prostate cancer patients with bone metastasis. |
| PubMedID- 22179324 | Purpose: we tried to establish the predictive factors influencing the initial response, as well as its duration, and time to castration resistance (cr) for primary advanced prostate cancer (pc) with bone metastasis. |
| PubMedID- 22993586 | Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data. |
| PubMedID- 21365645 | Steps in prostate cancer progression that lead to bone metastasis. |
| PubMedID- 24036918 | Clinical features and treatment strategies for older prostate cancer patients with bone metastasis. |
| PubMedID- 23368843 | Since bone metastasis is a hallmark of advanced prostate cancer and is detected in at least 85% of patients who die of this disease, it is of great importance to understand the regulation of the cellular signaling pathways involved in the metastatic process. |
| PubMedID- 25943311 | Notch1 expression in bone metastases is significantly higher than that in primary tumorsand, and may play an important role in the bone metastasis of prostate cancer . |
| PubMedID- 26011628 | Previous studies have shown expression of cemp1 in breast and prostate cancer with bone metastasis and in mcf-7 and pc3 cell lines . |
| PubMedID- 21206493 | bone metastasis of prostate cancer is the major cause of morbidity and mortality, and was detected at autopsy in up to 90% of patients who died from prostate cancer (bubendorf et al, 2000). |
| PubMedID- 23951060 | Diminished expression of mir-143 and 145 was found in prostate cancer patients with bone metastasis . |
| PubMedID- 21358069 | Management of bone metastasis arising from prostate cancer. |
| PubMedID- 22537906 | Bmp4 plays an important role in bone metastasis of prostate cancer , and bmp4 overexpression inhibits proliferation and induces apoptosis in many cancer cell line . |
| PubMedID- 26225253 | The natural history of prostate cancer with bone metastasis development, accounting for up to 90% of patients, induces a bias in the assessment of treatment efficacy, because most of these lesions are poorly assessable with morphological imaging techniques and response evaluation criteria in solid tumors (recist) criteria.2 as a consequence, other indicators of treatment effects have been developed. |
| PubMedID- 22805007 | Clinical usefulness of bone markers in prostate cancer with bone metastasis. |
| PubMedID- 23404044 | bone metastasis of prostate cancer is frequent and generally manifold and osteoblastic (2). |
| PubMedID- 26097428 | bone metastasis in prostate cancer are detected by choline positron emission tomography/computed tomography (pet/ct) with high sensitivity and specificity. |
| PubMedID- 22035283 | A femoral bone metastasis of prostate cancer was removed during hemiarthroplasty and transplanted into rag2-/-;γc-/- mice either intra-femorally or sub-cutaneously. |
| PubMedID- 21754986 | A: radical prostatectomy specimen (gleason 4+3), b: bone metastasis of prostate cancer, c: bone metastasis of prostate cancer, d: radical prostatectomy specimen (gleason 4+3), e: castration-resistant prostate cancer (gleason 5+5), f: palliative transurethral resection of prostate cancer (gleason 4+5), g: bone metastasis of prostate cancer, h: palliative transurethral resection of prostate cancer (gleason 5+4), i: castration-resistant prostate cancer (gleason 5+4). |
| PubMedID- 25531317 | Here, we demonstrate that tgfbeta regulates the level of microrna-96 (mir-96) through smad-dependent transcription and that mir-96 promotes the bone metastasis in prostate cancer. |
| PubMedID- 25862631 | On the other hand, the expression of human kallikrein 1-related peptidase (klk) 4, which activates plasma hgf activator zymogen, in prostate cancer patients with bone metastasis or advanced stage has also been reported. |
| PubMedID- 24773608 | Nadir psa <0.2 ng/ml and longer time to nadir (>9 months) during padt are the most important early predictors for survival in prostate cancer patients with bone metastasis . |
| PubMedID- 24858569 | Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis. |
| PubMedID- 21754927 | Twelve patients suffering from hormone-refractory prostate cancer with multiple bone metastasis underwent surgical castration under spinal or total anesthesia without leaving testicular capsule between october, 2008 and august, 2010. there were no complications associated with surgery. |
| PubMedID- 25354720 | Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis. |
| PubMedID- 22084798 | We aimed at assessment of effects of zoledronic acid therapy on bone metabolic indicators in hormone-resistant prostate cancer patients with bone metastasis. |
| PubMedID- 20206975 | Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. |
| PubMedID- 24466419 | Denosumab prevents bone metastasis in men with castration-resistant prostate cancer. |
| PubMedID- 22336908 | Significant addition to treatment options for bone metastasis in prostate cancer. |
| PubMedID- 23874600 | prostate cancer patients with bone metastasis have been shown to have high expression of β2-microglobulin (β2-m) in the cancer cells 2. |
| PubMedID- 22900098 | For example, an endothelin a receptor antagonists zd4054, has been shown to improve the overall survival and reduce the risk of death and bone metastasis in patients with resistant prostate cancer . |
| PubMedID- 22124112 | (b, top) representative images of immunohistochemical staining for bmpr2 on prostate cancer patient samples with or without bone metastasis. |
| PubMedID- 24387195 | Winkelmann and colleagues investigated micro ct in a bone metastasis model of prostate cancer in mice and found that bone micro ct was able to non-invasively follow the onset and progression of bone metastatic lesions as small as 300 μm in diameter 5. |
| PubMedID- 25887999 | High vimentin expression has been reported in bone metastasis of prostate cancer and has been implicated in prostate cancer cell invasion . |
| PubMedID- 22229077 | Dynamic contrast-enhanced mr imaging findings of bone metastasis in patients with prostate cancer. |
| PubMedID- 25374898 | Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis. |
| PubMedID- 24023317 | Aim: zoledronic acid (za) reduces the risk of skeletal-related events (sres) in castration-resistant prostate cancer (crpc) with bone metastasis and improves quality of life. |
| PubMedID- 25476483 | prostate cancer patients with bone metastasis exhibit elevated expression of β2-microglobulin (β2-m), which is a cell membrane protein (josson et al., 2013). |
| PubMedID- 26251788 | Although rare, dural metastasis should be considered among the differential diagnoses in a patient known for prostate cancer, particularly with bone metastasis. |
| PubMedID- 21556025 | bone metastasis in prostate cancer: emerging therapeutic strategies. |
| PubMedID- 21520153 | Since hormone refractory prostate cancer with bone metastasis is difficult to treat, it is crucial to investigate how androgen independent (ai) human prostate cancer cells communicate with their associated stroma. |
| PubMedID- 26366216 | In the same study, researchers also stated that zoledronate is only the bisphosphonate to show significant reduction in skeletal complications 46. yuen et al reviewed clinical trials on prostate cancer patients with bone metastasis and reported that there was no difference between the treatment and the control groups in prostate cancer death, disease progression, radiological and psa response 47. similarly, a study on patients with castration-sensitive prostate cancer and bone metastases reported that zoledronate did not affect the risk of skeletal-related events 48. on the other hand, another recent study (zeus: zometa european study) demonstrated that zoledronate is ineffective for the prevention of bone metastases in high risk prostate cancer patients at 4 year 49. however, further clinical and in vitro studies which enlighten the role of ddrs and mmps in different stages of disease may increase the therapeutic value of bisphosphonates in the treatment of prostate cancer. |
| PubMedID- 24026105 | Mir-145 is associated with bone metastasis of prostate cancer and may be involved in the regulation of emt by reducing the ability of migration and invasion in vitro, and tumor development and bone invasion in vivo of pc-3 cells (37). |
Page: 1 2